Tg Therapeutics 15min Chart Shows RSI Overbought, KDJ Death Cross

Based on the analysis of Tg Therapeutics's 15-minute chart, the RSI indicator has reached an overbought level and the KDJ indicator has triggered a death cross at 09/03/2025 09:45. This suggests that the stock price has risen too rapidly and is no longer supported by fundamental factors. Furthermore, the momentum of the stock price is shifting towards the downside, indicating a potential for further decreases in the future.

Tg Therapeutics Inc. (TGTX), a biopharmaceutical innovator specializing in therapies for B-cell malignancies and autoimmune disorders, has recently experienced significant changes in its stock price dynamics. Analyzing the 15-minute chart, the Relative Strength Index (RSI) indicator has reached an overbought level, suggesting that the stock price has risen too rapidly and may be unsupported by fundamental factors. Additionally, the KDJ indicator has triggered a death cross at 09:45 on September 3, 2025, indicating a potential shift in momentum towards the downside.

RSI and KDJ Indicators

The RSI, which measures the speed and change of price movements, has crossed above the 70 threshold, indicating overbought conditions. This level is typically seen when a stock has been rising too quickly and may be due for a correction. The KDJ indicator, which consists of three lines (K, D, and J) representing the average price, has seen a significant cross where the D line has crossed below the K line, a signal known as a death cross. This event often precedes a decline in stock prices.

Implications for Investors

For investors, these technical indicators suggest that the stock price of Tg Therapeutics may be overvalued and could experience a downward trend. The recent completion of a $100 million share repurchase program, authorized by the company's Board of Directors, may not be enough to support the stock price in the face of these technical signals. The company's participation in various industry conferences, including the Cantor Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference, could provide more insights into its strategic direction and market outlook.

Recent Financial Performance

Despite the technical indicators, Tg Therapeutics has reported strong financial results in recent quarters. The company's Q2 2025 financial results showed total revenue of $141.1 million, driven by BRIUMVI U.S. net revenue of $138.8 million, representing a 91% year-over-year growth and 16% growth over Q1 2025. The company raised its full-year 2025 revenue guidance to $570-575 million for BRIUMVI U.S. net revenue and approximately $585 million for total global revenue.

Conclusion

While Tg Therapeutics has shown strong financial performance, the technical indicators suggest that the stock price may be overvalued and could experience a downward trend. Investors should closely monitor the company's future earnings reports and strategic updates, especially given the upcoming conference calls and industry presentations. The technical signals should be taken into consideration alongside fundamental analysis to make informed investment decisions.

References

[1] https://www.stocktitan.net/news/TGTX/